Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Younger

Psychiatry Ridgeland, MS Medical Doctor

NPI 1598971830 CMS profile 27207

625 Highland Colony Parkway, Suite 101, Ridgeland, MS 39157

Open in the dashboard

General payments

$7,773

445 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Younger of Ridgeland, MS is reported in the CMS Open Payments database as having received $7,773 across 445 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $963 48
2024 General $805 41
2023 General $1,339 76
2022 General $1,239 68
2021 General $1,575 87
2020 General $616 43
2019 General $1,236 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Younger
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Susan Younger were reported at $963. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Susan Younger Psychiatry median Middle half National median
2019 $1,236 $184 $59–$605 $163
2020 $616 $119 $36–$372 $114
2021 $1,575 $143 $43–$576 $132
2022 $1,239 $153 $50–$590 $149
2023 $1,339 $170 $56–$651 $160
2024 $805 $179 $57–$673 $164
2025 $963 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,481 91 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,007 66 payments
  3. Otsuka America Pharmaceutical, Inc. $982 50 payments
  4. Vanda Pharmaceuticals Inc. $685 30 payments
  5. Supernus Pharmaceuticals, Inc. $355 23 payments
  6. Tris Pharma Inc $345 19 payments
  7. Axsome Therapeutics, Inc. $318 13 payments
  8. Allergan Inc. $286 28 payments
  9. Janssen Pharmaceuticals, Inc $285 19 payments
  10. Lundbeck LLC $283 13 payments
  11. Other $1,745 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,773 445 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,267 78 payments
  2. REXULTI $982 50 payments
  3. TRINTELLIX $771 48 payments
  4. FANAPT $685 30 payments
  5. HETLIOZ $517 24 payments
  6. VRAYLAR Neuroscience $495 40 payments
  7. Dyanavel XR $318 17 payments
  8. SPRAVATO $274 18 payments
  9. QELBREE $258 16 payments
  10. Dayvigo $229 13 payments
  11. Other $2,472 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,230

Median for Psychiatry & Neurology: 100

Drug cost

$35,624

Median for Psychiatry & Neurology: $2,986

Branded share of claims

21.9%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trileptal Oxcarbazepine Brand 12 $8,481
Lisdexamfetamine Dimesylate Generic 17 $3,857
Risperdal Risperidone Brand 12 $3,516
Temazepam Generic 39 $3,358
Eszopiclone Generic 11 $1,959
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 34 $1,829
Aripiprazole Generic 17 $1,481
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 50 $1,364
Clonazepam Generic 104 $1,245
Alprazolam Generic 204 $951

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $197
$197 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $126
$126 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $87
  • Lundbeck LLC $24
$112 — —
Sunosi
  • Axsome Therapeutics, Inc. $87
$87 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

445 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record